Early subthalamic nucleus deep brain stimulation in Parkinson's disease reduces long-term medication costs.

ABSTRACT:

Introduction

Subthalamic nucleus (STN) deep brain stimulation (DBS) is recognized as a safe and effective treatment in mid- and advanced-staged Parkinson's disease (PD) that decreases the need for PD medications and their associated costs. This study reports medication costs from the only clinical trial to evaluate DBS in patients with early-stage PD and projects costs through advanced-stage disease.

Methods

The DBS in early-stage PD pilot was a prospective, single-blind clinical trial that randomized 30 patients with early-stage PD 1:1 to receive bilateral STN-DBS plus optimal drug therapy (ODT) or ODT alone. Subjects who completed the trial participated in an observational follow-up study and were evaluated annually for five years after randomization. PD medication data co

SUBMITTER: Hacker M 

PROVIDER: S-EPMC8608728 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature